Supplements
    Fiber

    Fiber Supplements on GLP-1 Medications: Which to Choose

    Constipation is one of the most persistent side effects of GLP-1 medications. The right fiber supplement, taken correctly, can make a significant difference in your comfort.

    Last updated: December 18, 202513 min read

    Constipation affects 20-30% of semaglutide users and can persist well beyond the dose escalation period. While staying hydrated and eating fiber-rich foods are the first-line approaches, many patients on GLP-1 medications do not eat enough food to get adequate fiber from diet alone. That is where supplementation becomes essential. But not all fiber supplements are the same — choosing the right type and using it correctly makes all the difference.

    Types of Fiber Supplements Compared

    TypeBrand ExampleBest ForGas/Bloating
    Psyllium huskMetamucilGeneral regularityModerate
    MethylcelluloseCitrucelSensitive stomachsLow
    Wheat dextrinBenefiberTaste-free mixingLow-moderate
    Inulin/FOSVariousPrebiotic benefitsModerate-high
    Ground flaxseedBob's Red MillOmega-3s + fiberLow
    Chia seedsVariousHydration + fiberLow

    Psyllium Husk: The Gold Standard

    Psyllium husk (brand name Metamucil) is the most widely recommended fiber supplement for GLP-1 users. It is a soluble fiber that absorbs water and forms a gel-like substance that softens stool and promotes regular bowel movements.

    Benefits

    • Most clinical evidence for constipation relief
    • Also shown to lower LDL cholesterol (a bonus cardiovascular benefit)
    • Regulates both constipation and diarrhea (normalizes stool consistency)
    • Prebiotic effect — feeds beneficial gut bacteria
    • Available in powder, capsules, and wafers

    How to Use

    • Start with one serving (approximately 5g fiber) daily
    • Mix powder in 8 oz water and drink immediately (it gels quickly)
    • Drink an additional 8 oz water after taking
    • Increase to twice daily after 1-2 weeks if needed
    • Sugar-free versions are available and preferred for weight loss

    Methylcellulose: For Sensitive Stomachs

    If psyllium causes too much gas or bloating, methylcellulose (Citrucel) is an excellent alternative. It is a synthetic fiber that produces significantly less gas because it is not fermented by gut bacteria.

    • Best for: Patients who experience bloating or gas with other fiber supplements
    • Downside: Does not have the cholesterol-lowering benefits of psyllium
    • Dosing: Follow package directions, starting with one serving daily

    High-Fiber Foods for GLP-1 Users

    When you can eat, choose foods that pack fiber efficiently:

    • Chia seeds: 10g fiber per 2 tablespoons. Add to yogurt, smoothies, or water
    • Ground flaxseed: 4g fiber per 2 tablespoons. Also provides omega-3s
    • Black beans: 15g fiber per cup (if tolerated — beans may cause gas)
    • Avocado: 10g fiber per whole avocado
    • Berries: 4-8g fiber per cup depending on type
    • Broccoli: 5g fiber per cup
    • Oatmeal: 4g fiber per cup cooked

    Critical Rules for Fiber Supplementation

    Three Non-Negotiable Rules

    • 1. Always drink water with fiber. Fiber without adequate water can cause severe constipation or even bowel obstruction. Drink at least 16 oz water with every fiber serving.
    • 2. Increase gradually. Start low (5g/day) and increase by 2-3g per week. Sudden increases cause bloating, cramping, and gas.
    • 3. Separate from medications. Take fiber supplements at least 2 hours apart from oral medications, as fiber can impair absorption of some drugs.

    When to See Your Doctor

    Contact your healthcare provider if you experience:

    • No bowel movement for more than 3-4 days despite fiber, water, and stool softeners
    • Severe abdominal pain or bloating
    • Blood in stool
    • Vomiting with constipation (may indicate bowel obstruction — seek emergency care)

    For more on managing GI side effects, see our probiotics guide and magnesium guide. Visit our treatments page or learn how it works.

    Medical Disclaimer

    This article provides general supplement guidance. Consult your provider before starting fiber supplements, especially if you have a history of bowel obstruction, Crohn's disease, or other GI conditions.

    Comprehensive GLP-1 Care

    Trimi Health helps you manage every aspect of GLP-1 treatment including side effects.

    Get Started Today

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the published clinical evidence show for compounded semaglutide?

    Peer-reviewed evidence: Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021). Trimi offers compounded semaglutide starting at $99/month on the annual plan, dispensed by 503A community sterile compounding pharmacies (VialsRx — Texas pharmacy license #35264 — and GreenwichRx). Results vary by individual; eligibility is determined by a licensed clinician.

    Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. — STEP 1, NEJM 2021
    Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. — STEP 4, JAMA 2021
    Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. — SELECT, NEJM 2023

    Key Takeaways

    • Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021)
    • Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. (Source: STEP 4, JAMA 2021)
    • Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. (Source: SELECT, NEJM 2023)
    • Semaglutide is the active pharmaceutical ingredient; it is FDA-approved in the corresponding brand finished products (Wegovy and Ozempic). Trimi's compounded preparation of the same active ingredient is prepared per individual prescription by 503A community sterile compounding pharmacies and is not itself FDA-approved as a drug.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: March 15, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Amazing company and care team support! Fast response time, no hidden fees and they actually care enough to work with you and your needs on your weight loss journey. Down 12.5 pounds in 2 months!

    Outcome: Down 12.5 lbs in 2 months

    Sarah MillerFacebook
    Arrived within 24 hours. Easy to use. Comes with everything. The year is so worth it.

    Outcome: Same-day delivery experience

    Veronica LarimoreFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2032183
    2. Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA.Read StudyDOI: 10.1001/jama.2021.3224
    3. Garvey WT, Batterham RL, Bhatta M, et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine.Read StudyDOI: 10.1038/s41591-022-02026-4
    4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2307563
    5. Marso SP, Bain SC, Consoli A, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa1607141
    6. Perkovic V, Tuttle KR, Rossing P, et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2403347

    Was this article helpful?

    Keep Reading

    Complete guide to semaglutide 1.7mg dosing. Learn about expected weight loss results, side effects at this higher dose, and how to decide between staying at 1.7mg or advancing to 2.4mg.

    Complete guide to combining semaglutide and metformin. Learn about safety, synergistic benefits for diabetes and weight loss, GI side effect management, and dose adjustment considerations.

    Guide to semaglutide 0.5mg dose increase. Learn what to expect at the first titration step, typical side effects, weight loss results, and when to advance to 1.0mg.

    The most comprehensive 2026 guide to retatrutide, the triple GLP-1/GIP/glucagon agonist. Covers mechanism, Phase 2/3 trial data showing 24%+ weight loss, timeline to approval, side effects, and how to

    Start your GLP-1 journey — from $99/mo

    Get Started